Plain-English translation of NCT07029009 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called in people who have been diagnosed with MODY, a rare genetic form of diabetes. Researchers want to see whether this medication can not only help control blood sugar, but also improve digestive symptoms that people with MODY sometimes experience. The study will measure how your body responds to this treatment over time.
MODY is a genetic form of diabetes that is often misdiagnosed or undertreated because doctors don't fully understand how it works. This medication hasn't been thoroughly studied in MODY patients, so researchers want to learn whether it could be a helpful treatment option for this specific condition.
You likely qualify if…
You likely don't qualify if…
You will start with baseline tests to measure your blood sugar, metabolism, and digestive hormone levels. Then you'll begin taking the medication at a low dose, which will be gradually increased over three weeks to reach the target dose. Throughout the study, you'll have follow-up visits where researchers repeat blood tests and imaging to see how your body is responding to the treatment.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States
Testing effectiveness
Sponsor
Mansa
Enrollment target
~50 participants
Started
May 2025
Primary completion
August 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
10 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Mansa Krishnamurthy, M.D.
Children's Hospital Medical Center, Cincinnati
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.